Results 111 to 120 of about 52,225 (202)

In vivo eradication of human BCR/ABL-positive leukemia cells with an ABL kinase inhibitor.

Journal of the National Cancer Institute, 1999
P. L. Coutre, L. Mologni, L. Cleris, E. Marchesi, E. Buchdunger, R. Giardini, F. Formelli, C. Gambacorti-Passerini   +7 more
semanticscholar   +1 more source

Co-Occurrence of Jak2-Positive Myelofibrosis and Bcr-Abl-Positive Chronic Myelogenous Leukaemia Treated with Combination of Tyrosine Kinase Inhibitors and Ruxolitinib. [PDF]

Mediterr J Hematol Infect Dis
Paciaroni K, Campagna S, Villiva N, Maffini E, Celesti F, Tordi A, Lombardi M, Dragonetti G, di Toritto TC.   +8 more
europepmc   +1 more source

Abnormalities in Glucose Uptake and Metabolism in Imatinib-Resistant Human BCR-ABL–Positive Cells

Clinical Cancer Research, 2009
Douglas J. Kominsky, J. Klawitter, Jaimi L. Brown, L. Boros, J. Melo, S. Eckhardt, N. Serkova   +6 more
semanticscholar   +1 more source

Combination of intensive chemotherapy and imatinib can rapidly induce high-quality complete remission for a majority of patients with newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia.

Blood, 2004
M. Towatari, M. Yanada, N. Usui, J. Takeuchi, I. Sugiura, M. Takeuchi, F. Yagasaki, Y. Kawai, S. Miyawaki, S. Ohtake, I. Jinnai, K. Matsuo, T. Naoe, R. Ohno   +13 more
semanticscholar   +1 more source

Philadelphia Chromosome-negative, bcr/abl-positive Chronic Myelogenous Leukemia.

Journal of Nippon Medical School, 2001
Inokuchi, Koiti, Dan, Kazuo
openaire   +3 more sources

Clinical trials underestimate the age of chronic myeloid leukemia (CML) patients. Incidence and median age of Ph/BCR-ABL-positive CML and other chronic myeloproliferative disorders in a representative area in Germany

Leukemia, 2009
M. Rohrbacher, U. Berger, A. Hochhaus, G. Metzgeroth, K. Adam, T. Lahaye, Susanne Saussele, M. Müller, J. Hasford, H. Heimpel, Rüdiger Hehlmann   +10 more
semanticscholar   +1 more source

Identification of Bisindolylmaleimide IX as a potential agent to treat drug-resistant BCR-ABL positive leukemia. [PDF]

Oncotarget, 2016
Zhang X, Jia D, Ao J, Liu H, Zang Y, Azam M, Habib SL, Li J, Ruan X, Jia H, Wang X, Li B.   +11 more
europepmc   +1 more source

Hypusination of eukaryotic initiation factor 5A (eIF5A): a novel therapeutic target in BCR-ABL-positive leukemias identified by a proteomics approach.

Blood, 2007
S. Balabanov, A. Gontarewicz, P. Ziegler, U. Hartmann, W. Kammer, M. Copland, U. Brassat, M. Priemer, I. Hauber, T. Wilhelm, Gerold Schwarz, L. Kanz, C. Bokemeyer, J. Hauber, T. Holyoake, A. Nordheim, T. Brümmendorf   +16 more
semanticscholar   +1 more source

Hsp90 N- and C-terminal double inhibition synergistically suppresses Bcr-Abl-positive human leukemia cells. [PDF]

Oncotarget, 2017
Chen C, Zhuang Y, Chen X, Chen X, Li D, Fan Y, Xu J, Chen Y, Wu L.   +8 more
europepmc   +1 more source

A novel mechanism for imatinib mesylate-induced cell death of BCR-ABL-positive human leukemic cells: caspase-independent, necrosis-like programmed cell death mediated by serine protease activity.

Blood, 2004
Masayuki Okada, S. Adachi, T. Imai, Kenichiro Watanabe, S. Toyokuni, M. Ueno, A. Zervos, G. Kroemer, T. Nakahata   +8 more
semanticscholar   +1 more source